SAVA - NASDAQ

Cassava Sciences, Inc.

SAVA·NASDAQ

$1.96

-6.5%

HealthcareBiotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$94.44M

EPS-1.8800

P/E Ratio-1.04

Earnings Date03/16/2026

sava

Net Cash Provided by Financing Activities

Last Annual Value

-239.00K

3-Year CAGR

5-Year CAGR

10-Year CAGR

-18%

Adjust for Inflation

Cassava Sciences, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

SAVA · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Cassava Sciences, Inc. NASDAQ:SAVA	-239.00K	N/A	N/A	N/A
PepGen Inc. NASDAQ:PEPG	107.98M	N/A	-6.1%	N/A
Fate Therapeutics, Inc. NASDAQ:FATE	5.49M	301.2%	-58.6%	-21.0%
Assembly Biosciences, Inc. NASDAQ:ASMB	174.67M	132.9%	26.9%	102.2%
Codexis, Inc. NASDAQ:CDXS	27.93M	50.7%	49.3%	N/A
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	77.43M	N/A	4.9%	16.5%
Immuneering Corporation NASDAQ:IMRX	226.58M	99.7%	9.4%	N/A
Invivyd, Inc. NASDAQ:IVVD	215.63M	490.9%	-20.1%	N/A
OmniAb, Inc. NASDAQ:OABI	27.91M	N/A	23.5%	N/A
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO	88.33M	24.1%	N/A	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	594.00K	-53.6%	-71.3%	N/A

Cassava Sciences, Inc. Fair Value Envelope

SAVA · NASDAQ

Our analysis suggests that SAVA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.955, this represents a potential HIDDEN relative to our calculated worth for Cassava Sciences, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.955

Related Guides

Blog Categories

Continue your SAVA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.